An official website of the United States government
Home
Name
Venclexta
Alternate Names
Venetoclax
ABT 0199
ABT 199
GDC-0199
Abbreviations
None
Category
Chemotherapy
Subcategory
Cl-2 inhibitor
NSC Number
None
Primary Site
None
Histology
Remarks
October 23, 2020: Venclexta (venetoclax) has received FDA approval in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly-diagnosed acute myeloid leukemia in adults 75 years or older, or who have comorbidities precluding intensive induction chemotherapy.
May 15, 2019: FDA approved venetoclax (VENCLEXTA) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
April 11, 2016: FDA approved for treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. This agent is not usually given as first course treatment.
February 5, 2016: the FDA granted Venetoclax Breakthrough Designation for use in combination with hypomethylating agents for patients with untreated acute myeloid leukemia (AML) who are ineligible to receive standard induction therapy.
6/8/2018 FDA granted regular approval to venetoclax for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy
May 15, 2019: FDA approved venetoclax (VENCLEXTA) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
April 11, 2016: FDA approved for treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. This agent is not usually given as first course treatment.
February 5, 2016: the FDA granted Venetoclax Breakthrough Designation for use in combination with hypomethylating agents for patients with untreated acute myeloid leukemia (AML) who are ineligible to receive standard induction therapy.
6/8/2018 FDA granted regular approval to venetoclax for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy
Coding
This drug should be coded
